Trial Profile

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Botensilimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Panitumumab
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms BBOpCo

Most Recent Events

23 Feb 2025 According to an Agenus Inc media release, a Trial-in-Progress (TiP) poster data will be presented from this study at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California.
20 Nov 2024 Status changed from not yet recruiting to recruiting.
19 Sep 2024 Planned initiation date changed from 1 Jul 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com